PL has been tested for its synergistic anti-tumor effect in combination with TNF-related apoptosis-inducing ligand [46], ataxia telangiectasia and Rad3-related protein inhibition [50], or a chemotherapeutic agent, such as cisplatin [33, 34], paclitaxel [34], docetaxel [51], and gemcitabine [39]. The gene discussed is TNFSF10; the disease is Ataxia-telangiectasia.